About Nuo Therapeutics (OTCMKTS:CMXI)
Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:CMXI
- CUSIP: N/A
- Web: www.cytomedix.com
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -637.52%
- Return on Equity: -430.66%
- Return on Assets: -169.06%
Frequently Asked Questions for Nuo Therapeutics (OTCMKTS:CMXI)
What is Nuo Therapeutics' stock symbol?
Nuo Therapeutics trades on the OTCMKTS under the ticker symbol "CMXI."
Who are some of Nuo Therapeutics' key competitors?
Some companies that are related to Nuo Therapeutics include Banco Popolare (BPSAY), DAILY MAIL&GEN TST SPON (DMTGY), Solvay S.A. (SVYZY), Tencent Holding (TCEHY), Nestle SA (NSRGY), Cable & Wireless Communications Plc (CWIXF), L'Oreal SA (LRLCY), Naspers (NPSNY), Allianz SE (AZSEY), Basf Se (BASFY), Softbank Corp. (SFTBY), Volkswagen AG (VLKAY), Glencore International PLC, St. Helier (GLCNF), Glencore PLC (GLNCY), Australia & New Zealand Banking Group (ANZBY), National Australia Bank (NABZY), Reckitt Benckiser Group PLC (RBGLY) and Enel SpA (ENLAY).
Who are Nuo Therapeutics' key executives?
Nuo Therapeutics' management team includes the folowing people:
- David Emerson Jorden CPA, Chief Executive Officer, Chief Financial Officer, Director
- Peter A. Clausen Ph.D., Chief Science Officer
- Shaun C Martin, Chief Restructuring Officer
- Lawrence Atinsky, Director
- Paul D. Mintz M.D., Director
- Lyle A. Hohnke Ph.D., Independent Director
- Mark T. McLoughlin, Independent Director
- C. Eric Winzer, Independent Director
How do I buy Nuo Therapeutics stock?
Shares of Nuo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuo Therapeutics' stock price today?
MarketBeat Community Rating for Nuo Therapeutics (OTCMKTS CMXI)MarketBeat's community ratings are surveys of what our community members think about Nuo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nuo Therapeutics stock can currently be purchased for approximately $0.34.
Consensus Ratings for Nuo Therapeutics (OTCMKTS:CMXI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Nuo Therapeutics (OTCMKTS:CMXI)
Analysts' Ratings History for Nuo Therapeutics (OTCMKTS:CMXI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Nuo Therapeutics (OTCMKTS:CMXI)Earnings History by Quarter for Nuo Therapeutics (OTCMKTS CMXI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Nuo Therapeutics (OTCMKTS:CMXI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Nuo Therapeutics (OTCMKTS:CMXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nuo Therapeutics (OTCMKTS:CMXI)Insider Trades by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/6/2014||Dean Tozer||Insider||Buy||33,300||$0.36||$11,988.00|| |
|9/12/2014||Dean Tozer||Insider||Buy||40,000||$0.45||$18,000.00|| |
|8/29/2014||Dean Tozer||Insider||Buy||40,000||$0.35||$14,000.00|| |
|8/26/2014||Steven A Shallcross||CFO||Buy||27,500||$0.38||$10,450.00|| |
|8/22/2014||Dean Tozer||Insider||Buy||38,700||$0.38||$14,706.00|| |
|8/20/2014||Dean Tozer||Insider||Buy||48,000||$0.39||$18,720.00|| |
|8/20/2014||Martin P Rosendale||CEO||Buy||25,000||$0.40||$10,000.00|| |
|8/20/2014||Steven A Shallcross||CFO||Buy||52,000||$0.39||$20,280.00|| |
|5/21/2013||David Emerson Jorden||Director||Buy||80,000||$0.50||$40,000.00|| |
|4/19/2013||David Emerson Jorden||Director||Buy||50,000||$0.51||$25,500.00|| |
|4/9/2013||David Emerson Jorden||Director||Buy||75,000||$0.51||$38,250.00|| |
|4/4/2013||Martin P Rosendale||CEO||Buy||17,231||$0.52||$8,960.12|| |
|2/27/2013||David Emerson Jorden||Director||Buy||25,000||$0.52||$13,000.00|| |
|2/22/2013||Aldagen Holdings, Llc||Insider||Buy||281,819||$0.55||$155,000.45|| |
|2/22/2013||David Emerson Jorden||Director||Buy||50,000||$0.53||$26,500.00|| |
|2/22/2013||Martin P Rosendale||CEO||Buy||20,000||$0.53||$10,600.00|| |
|2/19/2013||Guercio Joseph Del||Director||Buy||509,091||$0.55||$280,000.05|| |
|9/14/2012||David Emerson Jorden||Director||Buy||25,000||$0.89||$22,250.00|| |
|9/11/2012||David Emerson Jorden||Director||Buy||8,333||$0.95||$7,916.35|| |
Headline Trends for Nuo Therapeutics (OTCMKTS:CMXI)
Latest Headlines for Nuo Therapeutics (OTCMKTS:CMXI)
Loading headlines, please wait.
Nuo Therapeutics (CMXI) Chart for Sunday, October, 22, 2017